Novartis maitained its strong position in the Dow Jones Sustainability World Index with a percentile score of 91 (vs. 87 in 2019). We are proud of our industry-leading performance in the areas of social and environmental reporting, human capital …
- Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2
- Follows establishment of multi-disciplinary expert coalition and Novartis commitment to sharing data and findings with ophthalmology community
- Despite existing therapies, significant unmet need still exists for wet AMD patients; data shows around half of patients have unresolved fluid, with a third requiring monthly injections3,4
Basel, November 13, …
- Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult patients and in three age categories1,2
- Sustained LDL-C reduction with inclisiran was observed regardless of age or gender differences1,2 with two doses a year, after an initial dose and then again at three months; the overall …
Translational immunologists from the Novartis Institutes for BioMedical …
- The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilation, or its key secondary endpoint of reduced COVID-19 mortality, compared with SoC1
- Ilaris® (canakinumab) remains an effective …
- Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx® at Week 12 vs. placebo, with improvements as early as Week 11
- ULTIMATE is the first ever Phase IIIb imaging study primarily looking at the time course of response to Cosentyx in biologic-naïve patients with active psoriatic arthritis (PsA) using Power Doppler ultrasonography (PDUS)1
- PDUS is a sensitive technology, allowing detection and monitoring of early changes in synovitis and enthesitis1 …
If you took all the people on Earth with atherosclerosis and moved them to a single country, it would be the most populous nation on the planet. Those relocated would wonder why they were chosen, because their condition – caused by high cholesterol – is invisible.
It is also potentially deadly.
Atherosclerosis, caused by a buildup of cholesterol that forms plaques in arteries, increases the risk of cardiovascular disease, such as a heart attack and stroke. Despite the availability of approved medicines, heart disease remains the No. 1 cause of death by chronic disease worldwide …
- The first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpoints
- Aimovig showed superior tolerability and efficacy against topiramate and provided a significant reduction in monthly migraine days (MMDs)
- Aimovig is the most prescribed anti-calcitonin gene-related peptide pathway (anti-CGRP) …
- Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises (VOCs) available for use in Europe
- Clinical data showed that use of Adakveo led to a significant reduction in the rate of VOCs and to fewer days spent in hospital
- VOCs disrupt patients’ lives physically, socially, and emotionally – and can increase risk of organ damage and early death
Basel, October 30, …
- Foundation for Biomedical Research and Innovation (FBRI) in Kobe, Japan becomes first CAR-T cell therapy commercial manufacturing site in Asia
- Novartis global CAR-T manufacturing footprint now spans four continents, bringing Kymriah closer to patients and healthcare professionals around the world
- Prestigious FBRI is recognized for its world-class expertise and established practice in CAR-T cell therapy
- Global CAR-T manufacturing growth includes recent FDA approval for further capacity expansion in the US, …